Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models

[1]  E. G. Varlamova.  Protein-protein interactions of ER-resident selenoproteins with their physiological partners. , 2020 .

[2]  Mrinalini,et al.  Venom peptide repertoire of the European myrmicine ant Manica rubida: identification of insecticidal toxins. , 2020, Journal of proteome research.

[3]  Varlamova Elena Gennadyevna.  Protein-protein interactions of ER-resident selenoproteins with their physiological partners. , 2020, Biochimie.

[4]  Andy Wai Kan Yeung,et al.  Reactive oxygen species (ROS) and their impact in neurodegenerative diseases: literature landscape analysis. , 2020, Antioxidants & redox signaling.

[5]  Xiong Zhang,et al.  Selenoprotein T Promotes Proliferation and G1-to-S Transition in SK-N-SH Cells: Implications in Parkinson's Disease. , 2019, The Journal of nutrition.

[6]  K. Double,et al.  Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease , 2019, Aging cell.

[7]  Yi-Xun Liu,et al.  Role of EZH2 in cell lineage determination and relative signaling pathways. , 2019, Frontiers in bioscience.

[8]  Subash C. Gupta,et al.  Health benefits of resveratrol: Evidence from clinical studies , 2019, Medicinal research reviews.

[9]  M. Hipp,et al.  The proteostasis network and its decline in ageing , 2019, Nature Reviews Molecular Cell Biology.

[10]  Y. Anouar,et al.  Selenoprotein T is a key player in ER proteostasis, endocrine homeostasis and neuroprotection , 2018, Free radical biology & medicine.

[11]  Y. Anouar,et al.  AMPK Activation of PGC-1α/NRF-1-Dependent SELENOT Gene Transcription Promotes PACAP-Induced Neuroendocrine Cell Differentiation Through Tolerance to Oxidative Stress , 2018, Molecular Neurobiology.

[12]  J. Cryan,et al.  Deletion of TLX and social isolation impairs exercise‐induced neurogenesis in the adolescent hippocampus , 2018, Hippocampus.

[13]  J. Obeso,et al.  Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification , 2017, Experimental Neurology.

[14]  M. Landry,et al.  Selenoprotein T is a novel OST subunit that regulates UPR signaling and hormone secretion , 2017, EMBO reports.

[15]  M. Hallett,et al.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[16]  R. Zukin,et al.  The emerging field of epigenetics in neurodegeneration and neuroprotection , 2017, Nature Reviews Neuroscience.

[17]  Harald H. H. W. Schmidt,et al.  The oxidative stress theory of disease: levels of evidence and epistemological aspects , 2017, British journal of pharmacology.

[18]  M. Newton,et al.  Identification of tissue‐specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics , 2017, Aging cell.

[19]  Shengdi Chen,et al.  Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease , 2016, Progress in Neurobiology.

[20]  Y. Anouar,et al.  Selenoprotein T Deficiency Leads to Neurodevelopmental Abnormalities and Hyperactive Behavior in Mice , 2016, Molecular Neurobiology.

[21]  A. Merrill,et al.  Delineating pathological pathways in a chemically induced mouse model of Gaucher disease , 2016, The Journal of pathology.

[22]  V. Sartorelli,et al.  Polycomb Ezh2 controls the fate of GABAergic neurons in the embryonic cerebellum , 2016, Development.

[23]  BoukhzarLoubna,et al.  Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. , 2016 .

[24]  Sebastian A. Leidel,et al.  A Dynamic Unfolded Protein Response Contributes to the Control of Cortical Neurogenesis. , 2015, Developmental cell.

[25]  T. Beach,et al.  Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease , 2015, BMC Medical Genomics.

[26]  K. Igarashi,et al.  Reduced Adult Hippocampal Neurogenesis and Cognitive Impairments following Prenatal Treatment of the Antiepileptic Drug Valproic Acid , 2015, Stem cell reports.

[27]  Harald H. H. W. Schmidt,et al.  Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications , 2015, Antioxidants & redox signaling.

[28]  A. Cuadrado,et al.  Pharmacology and Clinical Drug Candidates in Redox Medicine , 2015, Antioxidants & redox signaling.

[29]  A. Aly,et al.  Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier , 2015, Expert opinion on drug delivery.

[30]  C. Counsell,et al.  Mortality in Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[31]  D. Gonzalez-Dunia,et al.  A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease , 2014, Nature Communications.

[32]  B. Carlson,et al.  Impaired selenoprotein expression in brain triggers striatal neuronal loss leading to co-ordination defects in mice. , 2014, The Biochemical journal.

[33]  A. Fernandes,et al.  Protective effects of the thioredoxin and glutaredoxin systems in dopamine-induced cell death. , 2014, Free radical biology & medicine.

[34]  V. Gladyshev,et al.  Selenoproteins: molecular pathways and physiological roles. , 2014, Physiological reviews.

[35]  M. Hayden,et al.  IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice , 2014, Molecular Neurobiology.

[36]  F. Hyder,et al.  Intranasal epidermal growth factor treatment rescues neonatal brain injury , 2013, Nature.

[37]  F. Pattou,et al.  The PACAP-regulated gene selenoprotein T is abundantly expressed in mouse and human β-cells and its targeted inactivation impairs glucose tolerance. , 2013, Endocrinology.

[38]  M. Chesselet,et al.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease , 2013, Progress in Neurobiology.

[39]  M. Sekutowicz,et al.  Rapid cell death is preceded by amyloid plaque-mediated oxidative stress , 2013, Proceedings of the National Academy of Sciences.

[40]  L. Bubacco,et al.  Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  O. Hwang.  Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.

[42]  M. Garcia-Conesa,et al.  Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery Disease , 2012, Cardiovascular Drugs and Therapy.

[43]  D. Surmeier,et al.  Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson’s disease , 2012, Nature Neuroscience.

[44]  N. Muzyczka,et al.  Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  H. Schmidt,et al.  The NOX toolbox: validating the role of NADPH oxidases in physiology and disease , 2012, Cellular and Molecular Life Sciences.

[46]  J. Poirier,et al.  The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain , 2012, Experimental Neurology.

[47]  I. Ferrer,et al.  Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease , 2011, Journal of Neural Transmission.

[48]  D. Surmeier,et al.  The origins of oxidant stress in Parkinson's disease and therapeutic strategies. , 2011, Antioxidants & redox signaling.

[49]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[50]  A. Manning-Boğ,et al.  Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain , 2011, Molecular Neurodegeneration.

[51]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[52]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[53]  B. Carlson,et al.  Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  E. Huang,et al.  Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[55]  J. Lesage,et al.  Selenoprotein T is a PACAP‐regulated gene involved in intracellular Ca2+ mobilization and neuroendocrine secretion , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  M. Bollen,et al.  The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing , 2008, Oncogene.

[57]  J. Rivas,et al.  Laser microdissection and microarray analysis of the hippocampus of Ras-GRF1 knockout mice reveals gene expression changes affecting signal transduction pathways related to memory and learning , 2007, Neuroscience.

[58]  L. Moran,et al.  The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability , 2007, Neurogenetics.

[59]  V. Bolivar,et al.  Habituation in rodents: A review of behavior, neurobiology, and genetics , 2006, Neuroscience & Biobehavioral Reviews.

[60]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  A. Scarpa,et al.  Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway , 2005, Oncogene.

[62]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[63]  E. Bézard,et al.  Spontaneous long‐term compensatory dopaminergic sprouting in MPTP‐treated mice , 2000, Synapse.

[64]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[65]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[66]  S. Fahn,et al.  Management of tardive dyskinesia , 1988, Drug and therapeutics bulletin.

[67]  W. Jeong,et al.  Role of resveratrol in regulation of cellular defense systems against oxidative stress , 2018, BioFactors.

[68]  E. Mariman,et al.  The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men , 2014, International Journal of Obesity.

[69]  Jun Chen,et al.  Intranasal Delivery of Granulocyte Colony-Stimulating Factor Enhances Its Neuroprotective Effects Against Ischemic Brain Injury in Rats , 2014, Molecular Neurobiology.

[70]  E. Junn,et al.  The role of oxidative stress in Parkinson's disease. , 2013, Journal of Parkinson's disease.

[71]  T. Dawson,et al.  The role of parkin in familial and sporadic Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[72]  M. Iida,et al.  Past , 1971, PS: Political Science & Politics.